b.婦人科がんにおける分子標的療法(4.腫瘍)

概要

論文の詳細を見る
With the advances in molecular biology, therapeutic drugs that target molecules mutated by cancer cells have been developed and gradually introduced into clinical practice. Because of minimum side effects, molecule-targeting drugs are expected not only to improve the quality of life, but also to have a beneficial effect on cost performance. These drugs are also expected to selectively exert their anti-tumor effects on cancer cells that are expressing target molecules. For example, herceptin, which has attracted attention in recent years, is a drug developed as an inhibitor against oncogene products, and p53 gene, a representative anti-oncogene, has been applied to gene therapy, to induce apoptosis in cancer cells. More, therapeutic drugs that target factors regulating the cell cycle of cancer cells or those regulating vascularization, which is essentially required for infiltation and metastasis of cancer cells, have already been used in clinical practice. Studies on these new drugs have tremendously deepened our understanding of cancer nature and individual constitutions, being expected to markedly improve cancer prevention and treatment.
社団法人日本産科婦人科学会の論文
2002-08-01